Lv71
5000 积分 2022-09-27 加入
Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis
14天前
已完结
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience
2个月前
已关闭
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
2个月前
已关闭
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
2个月前
已完结
Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study
2个月前
已完结
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
2个月前
已完结
GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma
2个月前
已完结
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
2个月前
已完结
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications
2个月前
已完结
Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants
2个月前
已完结
皖公网安备34019202002308
